Pular para o conteúdo
Papilomatose respiratória recorrente
ORPHA:60032CID-10 · J98.8CID-11 · 2F00.1DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
lungInício infânciaHerança Unknown

A papilomatose respiratória recorrente é uma doença respiratória rara caracterizada pelo desenvolvimento de papilomas exofíticos, acometendo a mucosa do trato aerodigestivo superior (com forte predileção pela laringe), causada por infecção pelo vírus do papiloma humano. Os sintomas de apresentação podem incluir rouquidão, tosse crônica, dispneia, infecções respiratórias superiores recorrentes, pneumonia, disfagia, estridor e/ou retardo de crescimento.

Última verificação: Fonte: sem afirmação sobre o SUS a verificarEm construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A papilomatose respiratória recorrente é uma condição respiratória rara provocada pela infecção pelo vírus do papiloma humano, caracterizada por lesões conhecidas como papilomas na mucosa da laringe e das vias aéreas. A família costuma perceber sinais como voz rouca constante, ruídos durante a respiração conhecidos como estridor, tosse frequente e episódios de engasgos ou dificuldade para respirar. No cenário mundial, existe medicamento aprovado pelo FDA norte-americano, como o PAPZIMEOS (zopapogene imadenovec), além de pesquisas avaliando novas terapias adjuvantes. No Brasil, a doença ainda não consta na lista oficial de Protocolos Clínicos e Diretrizes Terapêuticas do Ministério da Saúde, sendo o suporte clínico viabilizado pela rede pública assistencial de saúde.

📋
Informacoes curadas por IA — podem conter imprecisoes

A papilomatose respiratória recorrente é uma doença respiratória rara caracterizada pelo desenvolvimento de papilomas exofíticos, acometendo a mucosa do trato aerodigestivo superior (com forte predileção pela laringe), causada por infecção pelo vírus do papiloma humano. Os sintomas de apresentação podem incluir rouquidão, tosse crônica, dispneia, infecções respiratórias superiores recorrentes, pneumonia, disfagia, estridor e/ou retardo de crescimento.

Pesquisas ativas
9 ensaios
31 total registrados no ClinicalTrials.gov
Publicações científicas
1.131 artigos
Último publicado: 2026 Apr 16
Medicamentos
1 com registro
PAPZIMEOS (ZOPAPOGENE IMADENOVEC)

Tem tratamento?

✓ 1 medicamento específico desta doença (registro ANVISA, FDA ou SUS/CEAF)
PAPZIMEOS (ZOPAPOGENE IMADENOVEC)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
4.0
Netherlands
Início
Adolescent
+ adult, childhood, infancy
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: J98.8
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
9 sintomas
🫃
Digestivo
1 sintomas
📏
Crescimento
1 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

90%prev.
Voz rouca
Muito frequente (99-80%)
55%prev.
Desconforto respiratório
Frequente (79-30%)
55%prev.
Disfonia
Frequente (79-30%)
55%prev.
Morfologia anormal da traqueia
Frequente (79-30%)
17%prev.
Estridor
Ocasional (29-5%)
17%prev.
Insuficiência respiratória
Ocasional (29-5%)
23sintomas
Muito frequente (1)
Frequente (3)
Ocasional (12)
Muito raro (7)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 23 características clínicas mais associadas, ordenadas por frequência.

Voz roucaHoarse voice
Muito frequente (99-80%)90%
Desconforto respiratórioRespiratory distress
Frequente (79-30%)55%
DisfoniaDysphonia
Frequente (79-30%)55%
Morfologia anormal da traqueiaAbnormal trachea morphology
Frequente (79-30%)55%
EstridorStridor
Ocasional (29-5%)17%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.131PubMed
Últimos 10 anos200publicações
Pico202471 papers
Linha do tempo
2026Hoje · 2026🧪 1999Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Papilomatose respiratória recorrente

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 4 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

5 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

31 ensaios clínicos encontrados, 9 ativos.

Distribuição por fase
NCT07901738 · Zopapogene Imadenovec for the Treatment of Recurrent Respira…Em breve
PHASE3🇺🇸 Estados Unidos
NCT07339163 · Efficacy of Booster Injection With Gardasil-9 Vaccine on Int…Em breve
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07756840 · Combination Bevacizumab and PRGN-2012 in Adults With Recurre…Em breve
PHASE2🇺🇸 Estados Unidos
NCT04724980 · Adjuvant PRGN-2012 in Adult Patients With Recurrent Respirat…Ativo
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05879081 · Clinical Performance of Masimo MightySat Rx in Pediatric Pop…Concluído
NCT04398433 · INO-3107 With Electroporation (EP) in Participants With HPV-…Concluído
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT03707587 · M7824 in People With Recurrent Respiratory PapillomatosisConcluído
PHASE2🇺🇸 Estados Unidos
NCT02859454 · Avelumab for People With Recurrent Respiratory Papillomatosi…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02632344 · Pembrolizumab for HPV-associated Recurrent Respiratory Papil…Concluído
PHASE2🇺🇸 Estados Unidos
NCT02592902 · Recurrent Respiratory Papillomatosis and Extraesophageal Ref…Concluído
NA🇨🇿 Tchéquia
NCT02217358 · Value of Narrow Band Imaging (NBI) Endoscopy in the Early Di…Concluído
NA🇨🇿 Tchéquia
NCT01375868 · Effect of Vaccination in Patients With Recurrent Respiratory…Concluído
PHASE3🇨🇿 Tchéquia
NCT01020747 · Bevacizumab for Treatment of Recurrent Respiratory Papilloma…Concluído
PHASE1🇺🇸 Estados Unidos
NCT00571701 · Study of Celebrex (Celecoxib) in Patients With Recurrent Res…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00550914 · Multi-Center, Randomized Trial of the Pulsed Dye Laser for J…Concluído
🇺🇸 Estados Unidos
NCT00038714 · A Trial Study of SGN-00101 in Treating Pediatric Patients Wi…Concluído
PHASE2🇺🇸 Estados Unidos
NCT00205374 · Use of Cidofovir for Recurrent Respiratory PapillomatosisConcluído
PHASE4
NCT03465280 · Airway Intervention Registry (AIR): Recurrent Respiratory Pa…UNKNOWN
🇬🇧 Reino Unido
NCT02854761 · Safety Study of EF-022 in Adults With Recurrent Respiratory …UNKNOWN
PHASE1
NCT02555800 · Bevacizumab Versus Cidofovir for the Treatment of Recurrent …UNKNOWN
PHASE2🇲🇽 México
NCT01995721 · 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillom…UNKNOWN
PHASE3Hungary
NCT00747461 · Interventional Cryotherapy for the Eradication of Benign Air…Encerrado
PHASE4🇺🇸 Estados Unidos
NCT05215249 · Optiflow vs. Convential Anesthesia During Pediatric Laryngea…Cancelado
PHASE1, PHASE2
NCT01058317 · Propranolol Administration in Pediatric Patients With Recurr…Cancelado
PHASE2, PHASE3
NCT00829608 · Therapeutic Treatment With Human Papillomavirus Quadrivalent…Cancelado
EARLY_PHASE1🇺🇸 Estados Unidos
NCT00733252 · Optical Coherence Tomography of the Airway for Lung Cancer o…Cancelado
🇺🇸 Estados Unidos
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
564 papers (10 anos)
#1

Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols.

PloS one2026

Adjuvant intralesional administration of bevacizumab has shown promising effects in the management of recurrent respiratory papillomatosis (RRP). However, the optimal therapeutic parameters remain undefined. This prospective study aimed to compare the efficacy of two distinct intralesional bevacizumab administration protocols following surgical resection of RRP. Between 15/09/2023 and 31/12/2024, adult patients with RRP were enrolled in a prospective research study. Participants were allocated to one of two bevacizumab administration protocols, delivered intralesional during direct microlaryngoscopy and CO₂ laser excision. Disease severity was assessed using the Derkay, Dikkers and Numerical scoring systems, as well as the Voice Handicap Index (VHI), at baseline and at 8-week intervals. Both treatment regimens were associated with reduction in disease burden and improved voice outcomes. No statistically significant differences in disease control were observed between the two administration protocols. This study indicates that both dosing regimens of bevacizumab were effective as an adjunctive therapy of recurrent respiratory papillomatosis. The higher intralesional doses of bevacizumab are relatively safe and well tolerated in adult patients with laryngeal RRP. Further studies with extended follow-up are warranted to define long-term efficacy and optimal dosing strategies.

#2

Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026 Mar 18

To investigate the surgical and voice outcomes associated with office-based laryngeal surgery for the treatment of recurrent respiratory papillomatosis (RRP). PubMed, Google Scholar, and Cochrane databases. Two independent investigators search databases for studies reporting surgical or voice quality outcomes of patients treated with office-based surgery for RRP according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Primary outcomes consisted of surgical (safety, patient tolerance, recurrence, complications, number of interventions) and voice quality (subjective, aerodynamic, and acoustic measurements) outcomes. The bias analysis was conducted through the Methodological Index for Non-Randomized Studies (MINORS). Fifteen studies (13 retrospective, 2 prospective) met inclusion criteria, accounting for 357 patients with RRP mainly treated with PDL, KTP, and Blue Laser office-based surgery. Surgical outcomes reported 50% to 95.8% lesion regression rates. The patient tolerance was good, with smokers reporting the low level of tolerance. The cumulative complication rate was low (1.62%). Voice quality assessments demonstrated significant improvements in subjective measures (VHI-10, GRBAS), while there was no study reporting multidimensional voice quality assessments including subjective, perceptual, aerodynamic, and acoustics measurements. Methodological quality of included studies was low-to-moderate (MINORS scores: 5-9), with inconsistent reporting of confounding factors. Office-based laser surgery is a safe and effective treatment for vocal fold RRP, with an effective reduction of disease burden, satisfactory regression, and a moderate rate of subsequent need for OR management. Future studies are needed to investigate the long-term multidimensional voice quality outcomes related to office-based procedures and to compare them with operating room procedures.

#3

Risk factors for perioperative respiratory adverse events and unplanned intensive care admission in children with juvenile-onset recurrent respiratory papillomatosis undergoing carbon dioxide laser resection.

World journal of pediatric surgery2026

To identify risk factors for perioperative respiratory adverse events (PRAEs) and unplanned intensive care admission (UIA) in children with juvenile-onset recurrent respiratory papillomatosis (JORRP) undergoing carbon dioxide (CO₂) laser resection. This retrospective nested case-control study included 148 JORRP patients who underwent CO₂ laser resection between 2014 and 2023 at Sun Yat-sen Memorial Hospital. Univariate and multivariate logistic regression analyses were used to identify independent risk factors. Predictive nomograms were constructed based on the multivariate model. PRAEs were defined as laryngeal edema, bronchospasm, desaturation, emergency reintubation, or tracheostomy occurring within 24 hours post-surgery. Forty patients (27.0%) required UIA, of whom 36 (24.3% of the total cohort) experienced PRAEs that led to ICU admission. Median age at surgery was 3.8 years. Female sex (OR=4.00, 95% CI 1.07 to 15.87), number of previous surgeries (OR=16.05, 95% CI 3.86 to 66.78), younger age (per year increase, OR=0.70, 95% CI 0.53 to 0.94), longer duration of surgery (OR=1.01, 95% CI 1.01 to 1.02), and tracheal involvement (OR=5.58, 95% CI 1.27 to 24.55) were identified as significant independent risk factors for PRAEs. Similar patterns were observed for UIA. Nomogram analysis demonstrated that young female patients with multiple previous surgeries, prolonged surgical times, and tracheal tumors had the highest risk of respiratory complications. Patients who are female, younger, have tracheal involvement, multiple previous surgeries, and prolonged operative duration are at significantly higher risk for PRAEs and UIA following CO₂ laser resection for JORRP. These findings provide valuable insights for optimizing perioperative management and improving patient safety in this vulnerable population.

#4

Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.

Journal for immunotherapy of cancer2026 Feb 20

Therapeutic vaccines include DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP) and recombinant virus platforms. Only two therapeutic vaccines for neoplastic disease were approved by the Food and Drug Administration in the past 40 years: sipuleucel-T, approved in 2010 for hormone-resistant metastatic prostate cancer and targeting prostate acid phosphatase; and zopapogene imadenovec, approved in 2025 for recurrent respiratory papillomatosis, a rare, non-malignant but often invalidating disease caused by human papillomavirus (HPV) type 6 or type 11. In the last decade, DNA, mRNA and SLP vaccines directed against mutation-derived neoantigens have shown strong immunogenicity for T cells and clinical activity with or without additional immune checkpoint inhibition. Vaccine monotherapy is effective in premalignant disorders caused by high-risk HPV16 and virus-negative colonic polyps. Treatment of bulky or recurrent/metastatic (R/M) disease requires combination with surgery and/or chemotherapy or combination with an immune checkpoint inhibitor such as PD-1 blocker. In a recent study, adjuvant treatment with neoantigen-specific mRNA vaccine plus PD-1 blocker led to less melanoma recurrence than PD-1 blocker alone. In another randomized study, patients with R/M HPV16+ head and neck cancer only benefited from the combination of HPV16-specific SLP vaccine and a PD-1 blocker if they had high pretreatment PD-L1 biomarker expression in cancer tissue. Increasingly, biomarker-guided therapy is recommended.

#5

The Patient Perspective of Living With Recurrent Respiratory Papillomatosis.

The Laryngoscope2026 Feb 20

Recurrent Respiratory Papillomatosis (RRP) is caused by human papillomavirus (HPV) types 6 and 11, and afflicts children (Jo-RRP, Juvenile-onset RRP) and adults (Ao-RRP, adult-onset RRP). The study objective was to describe the disease burden of RRP from three patient-relevant perspectives: economic, clinical, and humanistic. A retrospective descriptive analysis of responses to questionnaires captured within a linked Coordination of Rare Diseases (CoRDS) and the Recurrent Respiratory Papillomatosis Foundation (RRPF) (CoRDS/RRPF) patient registries from May 1, 2019, to July 31, 2023 was performed. Categorical variables were summarized using counts and proportions and continuous variables were summarized using means (standard deviations) and medians (interquartile ranges). Responses from 122 participants, 55% (67/122) Jo-RRP and 45% (55/122) Ao-RRP, were included. Forty-one percent (41/99) traveled more than 100 miles round trip to receive specialty care, and 61% (52/85) spent > 5% of their family income to pay for care. RRP resulted in increased absences from school [94% (17/18) for participants aged < 22] and work [85.5% (65/76) for participants aged > 22]. Moreover, 64.9% (48/74) of respondents perceived that RRP negatively impacted their careers. Feelings of isolation (70%) and depression (45.1%) were common, but less than 25% of respondents reported seeking mental health assistance. RRP leads to clinical, financial, and psychosocial burdens. Increased public awareness regarding HPV infection of the airway is needed, as this disease is preventable through HPV vaccination.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC746 artigos no totalmostrando 199

2026

Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
2026

Risk factors for perioperative respiratory adverse events and unplanned intensive care admission in children with juvenile-onset recurrent respiratory papillomatosis undergoing carbon dioxide laser resection.

World journal of pediatric surgery
2026

Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years.

Journal for immunotherapy of cancer
2026

The Patient Perspective of Living With Recurrent Respiratory Papillomatosis.

The Laryngoscope
2026

Successful Use of Argon Plasma Coagulation in the Treatment of Multiple Recurrent Lower Tract Papillomatosis: A Case Report.

Respirology case reports
2026

Intralesional bevacizumab as an adjuvant approach to recurrent respiratory papillomatosis: A prospective study on different treatment protocols.

PloS one
2025

Recurrent respiratory papillomatosis: Recent advances in HPV-6/HPV-11-targeted immunotherapy.

Asian Pacific journal of allergy and immunology
2026

Can we use peak expiratory flow rate monitoring in recurrent respiratory papillomatosis?

International journal of pediatric otorhinolaryngology
2026

Recurrent respiratory papillomatosis: is patient well-being related to anatomical manifestation?

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2026

Juvenile-Onset Recurrent Respiratory Papillomatosis and Human Papillomavirus Vaccine Uptake: A 19-Year Retrospective Cohort Study.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
2026

Nasal Sublesional Bevacizumab Injections as Adjuvant Treatment for Diffuse Sinonasal Exophytic Papillomas.

Journal of clinical medicine
2026

Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2024.

Communicable diseases intelligence (2018)
2026

Immunohistochemical Expression of p16 and Its Association with Recurrence in Adult-Onset Recurrent Respiratory Papillomatosis: A Preliminary Study.

Journal of voice : official journal of the Voice Foundation
2026

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP.

The Laryngoscope
2026

Contemporary management of recurrent respiratory papillomatosis: a survey of Australian otolaryngologists.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2026

Recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: A retrospective study.

Medicina clinica
2026

Aggressive Juvenile-Onset Respiratory Papillomatosis in a High HIV Prevalence Setting: Clinical Predictors of Severity in South Africa.

Open forum infectious diseases
2025

Codon usage bias of low-risk human papillomavirus types 6 and 11.

Antonie van Leeuwenhoek
2025

Validation of Narrow Band Imaging in Recurrent Respiratory Papillomatosis Using Severity Scales.

The Laryngoscope
2026

The use of intralesional & systemic bevacizumab in severe recurrent respiratory papillomatosis: A case report.

International journal of pediatric otorhinolaryngology
2025

Nationwide Survey on Recurrent Respiratory Papillomatosis in Japan: Analysis of Long-Term Patients.

The Laryngoscope
2025

[Application of transnasal humidified rapid-insufflation ventilatory exchange in anesthesia for juvenile-onset recurrent respiratory papillomatosis surgery].

Zhonghua yi xue za zhi
2025

From surgery to immunotherapy: Papzimeos as the first FDA-approved therapy for recurrent respiratory papillomatosis (RRP).

Annals of medicine and surgery (2012)
2025

Public health impact and cost-effectiveness of implementing gender-neutral immunization with the nonavalent human papillomavirus vaccine in South Korea.

Human vaccines &amp; immunotherapeutics
2026

In Reference to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis.

The Laryngoscope
2026

Zopapogene Imadenovec: First Approval.

Molecular diagnosis &amp; therapy
2026

Factors Influencing Laryngeal Web After Surgery Combined With Photodynamic Therapy in RRP.

The Laryngoscope
2026

In Response to A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis.

The Laryngoscope
2025

Is there a Role for Narrow Band Imaging (NBI) in the Identification of Recurrent Respiratory Papillomatosis (RRP)?

Journal of voice : official journal of the Voice Foundation
2025

Successful immunotherapy using adenovector gene therapy for the treatment of recurrent respiratory papillomatosis.

Molecular therapy : the journal of the American Society of Gene Therapy
2025

The Derkay Scale as a Predictor of Voice Dysfunction in Recurrent Respiratory Papillomatosis: Correlations Between Acoustic and Patient-Reported Outcomes.

Journal of clinical medicine
2025

Relationship between age at diagnosis and recurrence characteristics in adult-onset recurrent respiratory papillomatosis: a nationwide multicenter study from China.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan.

PloS one
2025

Pulmonary Dissemination in Adult-Onset Recurrent Respiratory Papillomatosis: A Rare and Severe Manifestation.

Respirology case reports
2026

Prolonged Treatment Gaps and Recurrence Patterns in Recurrent Respiratory Papillomatosis.

The Laryngoscope
2025

Relación entre genotipo y carga viral de virus del papiloma humano y la gravedad de presentación de la papilomatosis respiratoria recurrente en niños.

Boletin medico del Hospital Infantil de Mexico
2025

Standardisation of an AI-based vocal fold assessment tool on a recurrent respiratory papillomatosis model.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
2025

Recurrent lesion distribution after photodynamic therapy for recurrent respiratory papillomatosis.

Photodiagnosis and photodynamic therapy
2025

Chinese guideline for the diagnosis and treatment of juvenile-onset recurrent respiratory papillomatosis (2024).

World journal of otorhinolaryngology - head and neck surgery
2025

An exploratory study of human papillomavirus detection in oral rinses from patients with recurrent respiratory papillomatosis.

Fukushima journal of medical science
2025

HPV vaccination improves immune response in children with respiratory papillomatosis.

Scientific reports
2025

[Expert consensus on the early prevention of human papillomavirus related non-cervical diseases (2025 edition)].

Zhonghua yi xue za zhi
2025

DNA Immunotherapy (INO-3107) Results in Long-Term Surgery Reduction in RRP.

The Laryngoscope
2025

A Clinical Consensus Statement on Pulmonary Recurrent Respiratory Papillomatosis.

The Laryngoscope
2025

An Observational Study of the Prevalence of Oral Human Papilloma Virus Infection in Laryngologists.

The Laryngoscope
2025

[Expert consensus on comprehensive prevention and control strategies for human papillomavirus associated diseases].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
2025

The role of tumor-associated neutrophils in the pathogenesis of recurrent respiratory papillomatosis.

Journal of leukocyte biology
2025

Local T-Cell Dysregulation and Immune Checkpoint Expression in Human Papillomavirus-Mediated Recurrent Respiratory Papillomatosis.

Cells
2025

Should All Patients With Recurrent Respiratory Papillomatosis Be Vaccinated for HPV?

The Laryngoscope
2025

Recurrent respiratory papillomatosis causing critical airway obstruction in the third trimester of pregnancy.

BMJ case reports
2025

Human Papillomavirus Exposure Risk and Vaccination Awareness Among Laryngeal Surgeons: A Worldwide Survey Study.

The Laryngoscope
2025

Characteristics of juvenile-onset recurrent respiratory papillomatosis in China, 2011-2021: A hospital-based nationwide study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

A scoping review of human papillomavirus related data system in China.

BMC infectious diseases
2026

Impact of COVID-19 on management and outcomes of NHS patients with recurrent respiratory papillomatosis: evidence from a UK registry.

Annals of the Royal College of Surgeons of England
2025

Recurrent respiratory papillomatosis in children: coblation versus microdebrider.

The Journal of laryngology and otology
2025

Pathogenesis of recurrent respiratory papillomatosis and potential novel treatment strategies.

Auris, nasus, larynx
2025

Projected health and economic effects of nonavalent versus bivalent human papillomavirus vaccination in preadolescence in the Netherlands.

BMC medicine
2025

HPV6-Induced Gene Expression Signature in Recurrent Respiratory Papillomatosis.

The Laryngoscope
2025

Physician Attitudes Towards Corticosteroid Usage in Patients With Recurrent Respiratory Papillomatosis: A National Survey.

Journal of voice : official journal of the Voice Foundation
2025

Improved Tubeless Airway Management in JORRP Surgery: Comparative Analysis of Pre- and Post-THRIVE Implementation.

Therapeutics and clinical risk management
2025

Current treatment options for recurrent respiratory papillomatosis: A narrative review.

Auris, nasus, larynx
2025

Disease Control and Voice Outcomes Following Treatment With PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis.

Journal of voice : official journal of the Voice Foundation
2025

Dysplasia and Carcinoma in Recurrent Respiratory Papillomatosis Patients Older Than 45 Years.

The Laryngoscope
2024

A Case of Malignant Transformation of Recurrent Respiratory Papillomatosis That Was Effectively Treated with Pembrolizumab.

Case reports in oncology
2025

A young female with multiple cavitary lung lesions.

Respiratory medicine case reports
2025

HPV Infection in Children and Adolescents-A Comprehensive Review.

Journal of clinical medicine
2025

Laryngeal Papillomatosis.

Cancers
2025

Therapeutic Impact of Gardasil® in Recurrent Respiratory Papillomatosis: A Retrospective Study on RRP Patients.

Viruses
2025

Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2023.

Communicable diseases intelligence (2018)
2025

[Preoperative anesthesia risk assessment factors in young children with severe recurrent respiratory papillomatosis].

Zhonghua yi xue za zhi
2025

Update on Gardasil Vaccination in Recurrent Respiratory Papillomatosis Patients Aged 45 or Older.

The Laryngoscope
2025

A cost-effectiveness analysis of adult human papillomavirus vaccination strategies in Italy.

Human vaccines &amp; immunotherapeutics
2025

Major Human Leukocyte Antigen Expression in Respiratory Papillomatosis Clinical Specimens.

The Laryngoscope
2025

Nonlinear relationship between operational frequency and age in respiratory papillomatosis patients.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2025

Recurrent respiratory papillomatosis: role of bevacizumab and HPV vaccination. A literature review with case presentations.

Radiology and oncology
2025

Impact of HPV Types and Dendritic Cells on Recurrent Respiratory Papillomatosis' Aggressiveness.

Diseases (Basel, Switzerland)
2025

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.

Nature communications
2025

Recurrent respiratory papillomatosis in adults with lower respiratory tract involvement: a retrospective study of the OrphaLung and GETIF networks.

The European respiratory journal
2025

A high-impact study and landmark achievement in the treatment of recurrent respiratory papillomatosis.

The Lancet. Respiratory medicine
2025

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.

The Lancet. Respiratory medicine
2025

[Clinical observation on rapid relief of dyspnea in juvenile-onset recurrent respiratory papillomatosis treated with bevacizumab].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2024

Tinnitus and dementia risk, adjuvant treatments for recurrent respiratory papillomatosis and is frontal sinus pain a useful marker of chronic frontal sinusitis?

The Journal of laryngology and otology
2025

HPV Vaccination in a Case of JORRP, a Variety of RRP in Bangladesh Medical College Hospital: A Case Report.

Mymensingh medical journal : MMJ
2024

The Recurrence of Tracheobronchial Papillomatosis Following Prostate Cancer Diagnosis.

Cureus
2024

Emergency Debulking of Recurrent Respiratory Papillomatosis: An Anesthesia Challenge.

Cureus
2024

"A systematic literature review of the epidemiology, clinical, economic and humanistic burden in recurrent respiratory papillomatosis".

Respiratory research
2025

Trends in the incidence and prevalence of juvenile-onset recurrent respiratory papillomatosis following implementation of national HPV vaccination initiatives: a systematic review.

Acta oto-laryngologica
2025

Nationwide Survey on Incidence and Management of Recurrent Respiratory Papillomatosis in Japan.

The Laryngoscope
2025

Prevalence and risk factors for dysplasia and malignancy in a large cohort of patients with recurrent respiratory papillomatosis.

The Journal of laryngology and otology
2024

Long-Term Infection With a Particular Human Papillomavirus (HPV) Genotype, HPV Subtype, or HPV Genomic Variant Does not Significantly Influence the Clinical Course of Recurrent Respiratory Papillomatosis.

Journal of medical virology
2025

Recurrent respiratory papillomatosis: Immunological mechanisms involved in recurrence.

International reviews of immunology
2024

Genomic diversity of HPV6 and HPV11 in recurrent respiratory papillomatosis: Association with malignant transformation in the lungs and clinical outcomes.

Tumour virus research
2024

[Update on HPV-associated head and neck cancers-highlights of the 2024 ASCO Annual Meeting].

HNO
2025

Current Practice, Safety and Efficacy of Interventions for Recurrent Respiratory Papillomatosis: Evidence From a UK Registry.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology &amp; Cervico-Facial Surgery
2024

Effective control of a severely progressive recurrent respiratory papillomatosis with repetitive cryotherapy.

The Korean journal of internal medicine
2024

Recurrent Respiratory Papillomatosis in the Post-Human Papillomavirus Vaccination Era.

JAMA pediatrics
2024

Adjuvant treatments for recurrent respiratory papillomatosis: a descriptive review and proposed management guideline in adults.

The Journal of laryngology and otology
2024

Evaluating the efficacy and safety of intralesional bevacizumab in the treatment of recurrent respiratory papillomatosis: A systematic review.

International journal of pediatric otorhinolaryngology
2024

Advances in Recurrent Respiratory Papillomatosis Treatment: Adjuvant Intralesional Bevacizumab's Impact, Potential and Insights from a Case Series Study.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2024

Successful Bevacizumab Therapy in a 25-Year-Old Patient with Recurrent Respiratory Papillomatosis.

European journal of case reports in internal medicine
2024

Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.

JAMA network open
2024

[Recurrent respiratory papillomatosis].

Revue medicale suisse
2024

Recurrent respiratory papillomatosis: comparing in-office and operating room treatments.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
2024

Characterization of HPV6/11-reactive T-cell subsets in papillomas of patients with juvenile-onset recurrent respiratory papillomatosis and identification of HPV11 E7-specific candidate TCR clonotypes.

Journal of virology
2025

Quantifying Bevacizumab Efficacy in Recurrent Respiratory Papillomatosis.

The Laryngoscope
2025

Mucosal Injection of the Silicon Phthalocyanine Pc 4 in a Rabbit Model-A Pilot Study.

The Laryngoscope
2024

Forecasting Disease Burden with a Dynamic Transmission Model of Human Papillomavirus and Recurrent Respiratory Papillomatosis in the United States.

Viruses
2024

[Step treatment of invasive recurrent respiratory papillomatosis in children: a case report].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2024

Results of CO2 laser surgery in laryngeal papillomatosis.

Oral oncology
2024

Effectiveness of surgery combined with photodynamic therapy for recurrent respiratory papillomatosis.

American journal of otolaryngology
2024

Cell-free DNA analysis for recurrent respiratory papillomatosis: A case report.

Clinical case reports
2024

[Chinese guideline for the diagnosis and treatment of juvenile-onset recurrent respiratory papillomatosis (2024)].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
2024

Cough syncope and recurrent respiratory papillomatosis.

Lancet (London, England)
2024

A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis.

The Laryngoscope
2024

VEGF as a Key Actor in Recurrent Respiratory Papillomatosis: A Narrative Review.

Current issues in molecular biology
2024

Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review.

The Annals of otology, rhinology, and laryngology
2024

A Case Report of Juvenile-Onset Recurrent Respiratory Papillomatosis.

Cureus
2025

Quality of Life in Recurrent Respiratory Papillomatosis Patients after Vocal Fold Surgery: An In-Depth Exploration.

Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)
2024

Risk Factors for Procedural Complications of Pediatric Flexible Bronchoscopy: Experience From a Tertiary Care Centre in Northern India.

Indian pediatrics
2024

The clinical characteristics of 1894 cases of upper respiratory papillomatosis: A single-center retrospective analysis.

American journal of otolaryngology
2024

Global trends and hotspots on recurrent respiratory papillomatosis: A 20-year bibliometric analysis.

Laryngoscope investigative otolaryngology
2024

Is there any interplay between human gut microbiota and upper airway susceptibility to recurrent respiratory papillomatosis exacerbations?

Otolaryngologia polska = The Polish otolaryngology
2024

Remission of HPV-Related Diseases by Antivirals for Herpesvirus: Clinical Cases and a Literature Review.

Viruses
2024

Gardasil® as adjunctive therapy for respiratory papillomatosis at Red Cross Children's Hospital, Cape Town.

Journal of the colleges of medicine of South Africa
2024

[Translated article] Treatment of juvenile recurrent respiratory papillomatosis in a pediatric lung transplant recipient.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria
2024

Juvenile onset recurrent respiratory papillomatosis: What do we know in 2024 ?

Tumour virus research
2024

Healthcare Spending and Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.

Journal of voice : official journal of the Voice Foundation
2024

Effectiveness of combined approach to recurrent respiratory papillomatosis (RRP).

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2024

The role of HPV11 E7 in modulating STING-dependent interferon β response in recurrent respiratory papillomatosis.

Journal of virology
2024

Structured Literature Review to Identify Human Papillomavirus's Natural History Parameters for Dynamic Population Models of Vaccine Impacts.

Infectious diseases and therapy
2024

Human papillomavirus genotype distribution patterns in Zimbabwe; is the bivalent vaccine sufficient?

Intervirology
2024

Angiogenesis Inhibitor Drug-induced Benign Migratory Glossitis in a Patient of Juvenile-onset Recurrent Respiratory Papillomatosis under Maintenance Therapy.

International journal of clinical pediatric dentistry
2024

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.

The Laryngoscope
2024

Pulmonary Involvement in Recurrent Respiratory Papillomatosis: A Systematic Review.

Infectious disease reports
2024

Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden.

Acta oto-laryngologica
2024

Diode Laser for Juvenile Recurrent Respiratory Papillomatosis: A Case Series of 13 Patients.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2024

Clinico-pathological Factors in Malignant Transformation of RRP.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2024

Quantification and Functional Studies of Neutrophilic Cells Identifies Distinct Papilloma Phenotypes.

The Laryngoscope
2024

Investigating immune and non-immune cellular profiles in recurrent respiratory papillomatosis by multi-omics.

Clinical and translational medicine
2024

Cost-effectiveness of nonavalent HPV vaccination in the Netherlands.

Expert review of vaccines
2024

Adjuvant Human Papillomavirus Vaccination in Recurrent Respiratory Papilloma Patients Older than 45.

The Laryngoscope
2024

Clinical significance of type IV vascularization of laryngeal lesions according to the Ni classification.

Frontiers in oncology
2024

Off-label drugs in otolaryngological practice against the background of legal conditions of Polish legislation.

Otolaryngologia polska = The Polish otolaryngology
2024

Clinical evaluation of pediatric patients with recurrent respiratory papillomatosis.: A longitudinal study at a Saudi Arabian tertiary care center.

Saudi medical journal
2024

Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.

The Laryngoscope
2024

Systemic bevacizumab for treatment of recurrent respiratory papillomatosis.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2024

Factors Associated with Iatrogenic Laryngeal Injury in Recurrent Respiratory Papillomatosis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
2024

The Larynx is Protected from Secondary and Vertical Papillomavirus Infection in Immunocompetent Mice.

The Laryngoscope
2024

Cimetidine for recurrent respiratory papillomatosis in pregnancy as an alternative adjuvant treatment.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2024

A pilot study on salivary HPV DNA detection to monitor active disease from patients with recurrent respiratory papillomatosis.

American journal of otolaryngology
2024

Laryngeal office-based procedures: A safe approach.

American journal of otolaryngology
2023

A case report describing the use of systemic bevacizumab in the treatment of recurrent respiratory papillomatosis with pulmonary involvement.

Respirology case reports
2023

Tracheobronchopathia osteochondroplastica: a case report highlighting the importance of clinico-radiologic correlation.

BJR case reports
2023

Placental and Breast Metastasis of Squamous Cell Carcinoma in a Patient With Recurrent Respiratory Papillomatosis.

Cureus
2023

The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.

Science translational medicine
2024

Recurrent respiratory papillomatosis disease course in immunosuppressed populations.

The Journal of laryngology and otology
2024

Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2023

Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2022.

Communicable diseases intelligence (2018)
2024

Low-Dose Cisplatin-Based Radiation Therapy for Refractory Recurrent Respiratory Papillomatosis.

The Laryngoscope
2023

Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study.

Human vaccines &amp; immunotherapeutics
2024

Usefulness of Intraoperative Narrow-Band Imaging in the Site Diagnosis of Respiratory Papillomatosis.

The Laryngoscope
2024

HPV-related diseases in male patients: an underestimated conundrum.

Journal of endocrinological investigation
2023

Indications, Efficacy, Safety, and Clinical Outcomes of 585 nm Pulsed Dye Laser in Non-Malignant Laryngeal Lesions: A Systematic Review.

Journal of personalized medicine
2023

Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.

Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
2024

Environmental Sustainability: Waste Audit Comparison Operating Roomand In-Office Laryngeal Surgery.

The Laryngoscope
2025

Intralesional Cidofovir: A Systematic Review of Administration Protocols and Long-term Recurrence Rates in Adult and Juvenile Recurrent Respiratory Papillomatosis.

Journal of voice : official journal of the Voice Foundation
2023

Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.

Journal of medical economics
2023

Transnasal Humidified Rapid Insufflation Ventilatory Exchange Augments Oxygenation in Children With Juvenile Onset Recurrent Respiratory Papillomatosis During Surgery: A Prospective Randomized Crossover Controlled Trial.

Anesthesia and analgesia
2023

Recurrent respiratory papillomatosis (RRP) of tracheobronchial tree presenting as lung collapse with malignant transformation after a decade.

Respiratory medicine case reports
2023

Recent Developments in Human Papillomavirus (HPV) Vaccinology.

Viruses
2024

Efficacy of Systemic Bevacizumab for Recurrent Respiratory Papillomatosis with Pulmonary Involvement.

The Laryngoscope
2023

Role Of CO2 Laser & Microdebrider In The Treatment Of Juvenile Onset Recurrent Respiratory Papillomatosi.

JPMA. The Journal of the Pakistan Medical Association
2024

Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.

The Annals of otology, rhinology, and laryngology
2023

[Human papillomavirus prevalence and type distribution in Chinese juvenile-onset recurrent respiratory papillomatosis patients].

Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
2023

Recurrent laryngeal papillomatosis with pulmonary involvement: case report.

Revista peruana de medicina experimental y salud publica
2023

Laryngeal Suction tube: A Novel Technique for Tracheal Ventilation in an Obstructed Airway in a Child with Respiratory Papillomatosis.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2023

Intralesional Bevacizumab as Adjuvant Therapy for Juvenile Onset Recurrent Respiratory Papillomatosis: A Systematic Review.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2023

The incidence of juvenile onset recurrent respiratory papillomatosis at Starship Children's Hospital before and after a national HPV vaccination programme: a retrospective review.

The New Zealand medical journal
2023

Preclinical Models of Laryngeal Papillomavirus Infection: A Scoping Review.

The Laryngoscope
2024

Comparison of three different image enhancement systems for detection of laryngeal lesions.

The Journal of laryngology and otology
2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis.

The Laryngoscope
2023

Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: One single-center experience of eight patients.

Laryngoscope investigative otolaryngology
2023

Association between human papillomavirus particle production and the severity of recurrent respiratory papillomatosis.

Scientific reports
2023

Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy.

NPJ vaccines
2023

Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.

Vaccine
2023

Smoking and Carcinoma Trends in Recurrent Respiratory Papillomatosis Patients.

The Annals of otology, rhinology, and laryngology
2022

Our experience in developing and operating the Airway Intervention Registry for Recurrent Respiratory Papillomatosis (AIR-RRP): national data collection.

NIHR open research
2023

Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.

Head &amp; neck
2023

Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.

The Laryngoscope
2023

Molecular Mechanisms of Carcinogenesis in Pediatric Airways Tumors.

International journal of molecular sciences
2022

Experience with Systemic Bevacizumab in Advanced Juvenile Recurrent Respiratory Papillomatosis.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2022

Trace Elements Levels in Serum of Patients with Recurrent Respiratory Papillomatosis.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2022

Adult-onset Recurrent Respiratory Papillomatosis at a South African Referral Hospital.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2023

Clinical and Public Health Considerations for HPV Vaccination in Midadulthood: A Narrative Review.

Open forum infectious diseases
2022

Recurrent Respiratory Papillomatosis Presenting as Worsening Dyspnea in an HIV-infected Patient.

Cureus
2023

Surgical outcome of different surgical modalities for adult recurrent respiratory papillomatosis.

Acta oto-laryngologica
2023

Human papillomavirus vaccination in Africa: An airway perspective.

International journal of pediatric otorhinolaryngology
2022

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022.

Children (Basel, Switzerland)
2023

The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis.

The Laryngoscope
Ver todos os 746 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Papilomatose respiratória recorrente.

É de uma associação que acompanha esta doença? Fale com a gente →

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Papilomatose respiratória recorrente e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

A doença é causada pela infecção crônica do trato respiratório pelo vírus do papiloma humano. Essa infecção provoca o crescimento de papilomas na mucosa aerodigestiva, principalmente na região da laringe.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

9 publicações do grafo RarasNet (PubMed) · 6 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. Surgical and Voice Outcomes of Office-Based Recurrent Respiratory Papillomatosis Surgery: A Systematic Review.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026PMID 41848235
  2. ORPHA:60032
    Orphanet
  3. GARD:111
    GARD (NIH)
  4. Q3497004
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Papilomatose respiratória recorrente. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/papilomatose-respiratoria-recorrente

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Papilomatose respiratória recorrente
Compêndio · Raras BR

Papilomatose respiratória recorrente

ORPHA:60032 · MONDO:0018955
Prevalência
1-9 / 100 000
Herança
Not applicable
CID-10
J98.8 · Outros transtornos respiratórios especificados
CID-11
Ensaios
9 ativos
Início
Adolescent, Adult, Childhood, Infancy
Prevalência
4.0 (Netherlands)
MedGen
UMLS
C1168198
EuropePMC
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara